Welcome to our dedicated page for DOSEOLOGY SCIENCES news (Ticker: DOSEF), a resource for investors and traders seeking the latest updates and insights on DOSEOLOGY SCIENCES stock.
The DOSEF news page on Stock Titan provides a focused view of Doseology Sciences Inc., a biotechnology-driven consumer products company whose disclosures highlight IP-backed oral stimulant technologies and functional mushroom-based nutraceuticals. Company news offers insight into how Doseology presents its strategy across product development, regulatory planning, manufacturing and capital markets.
Recent releases describe Doseology’s work on precision-formulated oral stimulants and oral pouch technologies, including a partnership with McKinney Regulatory Science Advisors to guide formulation strategy, data generation, PMTA preparation and post-market compliance. News items also cover the company’s confidential manufacturing agreement, executed through its subsidiary Doseology USA Inc., with a North American partner operating an FDA-registered, GMP-certified and ISO 9001:2015-approved facility for oral pouch production.
Investors following DOSEF news can track updates on regulatory initiatives, manufacturing milestones and commercialization readiness for oral stimulant pouches, as well as Doseology’s commentary on consumer trends toward cleaner, controlled oral delivery formats. Earlier news provides context on the company’s evolution from a life sciences and mental health wellness focus, including functional mushroom tinctures, powders and supplements, to its current emphasis on biotechnology-driven consumer products.
Additional coverage includes capital-markets developments and investor communications, such as uplisting to the OTCQB Venture Market, DTC eligibility in the United States, and the launch of an Investor Communications Initiative with external advisory firms. Governance and management changes, strategic review announcements and facility decisions are also documented. For readers researching Doseology stock, this news feed serves as an organized archive of the company’s public statements on strategy, operations and market positioning.
Doseology (OTCQB: DOSEF) commenced trading on the OTCQB Venture Market on March 11, 2026, expanding U.S. investor access and aligning the company with higher reporting and governance standards. The company appointed Larry Latowsky as Executive Chairman and disclosed pre-funded warrant issuances tied to its Feed That Brain acquisition.
Doseology issued 75,000 pre-funded warrants at a deemed $1.00 price, with additional $75,000 issuances due at the one-year and 18-month anniversaries; the four-month hold on the initial warrants expires July 11, 2026.
Doseology (OTCQB: DOSEF) launched Feed That Brain® Energy Pouches in a U.S. direct-to-consumer pilot on March 4, 2026. The nicotine-free, caffeine-based oral pouches are available exclusively at feedthatbrain.com and Amazon.com, designed for portion-controlled, discreet stimulation without sugar, smoke, or liquid.
The pilot will evaluate consumer adoption, usage frequency, and repeat purchase behaviour to validate oral pouch delivery as a scalable stimulant platform. The company also granted 140,000 RSUs (vesting monthly over 36 months) and 210,000 PSUs tied to performance milestones.
Doseology (PINK:DOSEF; CSE:MOOD) appointed Larry Latowsky as director and Executive Chairman, effective February 18, 2026. The company granted 4,000 RSUs (36-month monthly vesting) and 6,000 PSUs tied to performance milestones. Doseology positions itself to scale precision oral stimulant delivery with strengthened governance and capital-markets expertise.
Latowsky brings pharmacy retail, manufacturing, and deal experience, including leadership roles at Katz Group and involvement in a ~C$3 billion transaction with McKesson.
Doseology (PINK: DOSEF) has begun a pilot production run of non‑nicotine, caffeine‑based energy pouches under its wholly owned Feed That Brain brand. The pilot is a limited direct‑to‑consumer initiative launching in the coming weeks and is exploratory, not a commercial roll‑out.
The pouch format emphasizes portioned, non‑liquid caffeine delivery focused on consistency, predictability, and user control. Doseology positions the pilot to gather product testing, consumer feedback, and operational learnings to inform future formulation, delivery design, and commercialization decisions.
Doseology (DOSED) filed its Annual Information Form (AIF) for the fiscal year ended June 30, 2025 on SEDAR+ to consolidate disclosure on business, strategy, risk factors, governance, and capital structure. The AIF aims to improve investor transparency and accessibility by combining information previously spread across multiple documents. The filing does not announce any financing or offering and is process-driven to maintain disclosure readiness and potential short-form prospectus eligibility under NI 44-101.
Doseology (ticker: DOSED) announced a strategic partnership with McKinney Regulatory Science Advisors to advance regulatory execution and commercial readiness for Doseology's oral pouch product portfolio. McKinney will advise on formulation strategy, data generation, Pre-market Tobacco Product Application (PMTA) preparation, labeling, and post-market compliance to support nicotine and nicotine-analogue pouch formats. The engagement aims to accelerate FDA pathway navigation, align R&D and manufacturing validation with regulatory expectations, strengthen IP and dose-consistency controls, and establish post-market surveillance and adverse-event reporting frameworks.
The collaboration is positioned to move Doseology from development toward regulated-market readiness while emphasizing consumer safety and regulatory-aligned product design.
Doseology (PINK: DOSEF) launched an Investor Communications Initiative on December 1, 2025 to strengthen disclosure, expand investor engagement, and support its commercial and capital‑markets strategy. The program includes a 3‑month engagement with Guerilla Capital (Dec 1, 2025–Feb 28, 2026) for $30,000 CAD, and a digital media agreement with Maynard Communications (commencing Dec 1, 2025; term listed to May 31, 2026) for $200,000 CAD. The company said the initiative will align reporting with governance standards, broaden retail and institutional visibility, and support commercialization of its oral stimulant platform. Regulatory disclosures state both firms or their principals currently hold Doseology securities and engagements are not at arm’s length; compensation is not tied to stock performance.
Doseology (PINK: DOSEF) announced that its wholly owned U.S. subsidiary, Doseology USA Inc., executed a confidential manufacturing agreement with a leading North American production partner on November 13, 2025. The partner operates an FDA-registered, GMP-certified, ISO 9001:2015 facility and offers end-to-end manufacturing for oral stimulant pouches including formulation, ingredient sourcing, pouch filling, packaging, and logistics. Doseology says the agreement provides scalable production from pilot runs to high-volume commercial output and establishes the operational and regulatory foundation to move from R&D toward market readiness in North America.
Summary not available.
Doseology Sciences Inc. (OTCQB: DOSEF) announced the resignation of CEO Ralph Olson and Director David Lutz, effective March 31, 2023. Pratik Patel, the Company’s CFO, has been appointed as interim CEO. The Company has granted 2,450,000 stock options at an exercise price of $0.10 per share. The strategic alternatives process initiated on January 23, 2023, is still ongoing, with further updates to be provided as necessary. This transition occurs amid Doseology's ongoing focus on developing functional fungi products aimed at addressing mental health challenges.